Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

George Liang King, M.D.

Concepts

This page shows the publications George King has written about Maleimides.
Connection Strength

1.226
  1. Can protein kinase C beta-selective inhibitor, ruboxistaurin, stop vascular complications in diabetic patients? Diabetes Care. 2005 Nov; 28(11):2803-5.
    View in: PubMed
    Score: 0.298
  2. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science. 1996 May 03; 272(5262):728-31.
    View in: PubMed
    Score: 0.154
  3. Glomerular-specific protein kinase C-ß-induced insulin receptor substrate-1 dysfunction and insulin resistance in rat models of diabetes and obesity. Kidney Int. 2011 Apr; 79(8):883-96.
    View in: PubMed
    Score: 0.107
  4. Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin. Expert Opin Drug Saf. 2006 Nov; 5(6):835-45.
    View in: PubMed
    Score: 0.080
  5. Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARgamma agonist's effects on edema and weight gain. FASEB J. 2006 Jun; 20(8):1203-5.
    View in: PubMed
    Score: 0.077
  6. Role of protein kinase C on the expression of platelet-derived growth factor and endothelin-1 in the retina of diabetic rats and cultured retinal capillary pericytes. Diabetes. 2003 Mar; 52(3):838-45.
    View in: PubMed
    Score: 0.062
  7. Protein kinase C and the development of diabetic vascular complications. Diabet Med. 2001 Dec; 18(12):945-59.
    View in: PubMed
    Score: 0.057
  8. Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation. Diabetes. 2000 Jul; 49(7):1239-48.
    View in: PubMed
    Score: 0.052
  9. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J. 2000 Mar; 14(3):439-47.
    View in: PubMed
    Score: 0.050
  10. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo : a specific vascular action of insulin. Circulation. 2000 Feb 15; 101(6):676-81.
    View in: PubMed
    Score: 0.050
  11. Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways. J Clin Invest. 1999 Jan; 103(2):185-95.
    View in: PubMed
    Score: 0.046
  12. Specific retinal diacylglycerol and protein kinase C beta isoform modulation mimics abnormal retinal hemodynamics in diabetic rats. Invest Ophthalmol Vis Sci. 1997 Dec; 38(13):2711-20.
    View in: PubMed
    Score: 0.043
  13. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes. 1997 Sep; 46(9):1473-80.
    View in: PubMed
    Score: 0.042
  14. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest. 1997 Jul 01; 100(1):115-26.
    View in: PubMed
    Score: 0.042
  15. Identification of the mechanism for the inhibition of Na+,K(+)-adenosine triphosphatase by hyperglycemia involving activation of protein kinase C and cytosolic phospholipase A2. J Clin Invest. 1995 Aug; 96(2):733-40.
    View in: PubMed
    Score: 0.037
  16. Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: role of oxidants and protein kinase-C activation. Diabetes. 2003 Mar; 52(3):829-37.
    View in: PubMed
    Score: 0.015
  17. Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart. Circulation. 1999 Jan 26; 99(3):384-91.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.